What are the latest news in the femtech market?
Download our beautiful pitch about the femtech market
In our femtech market deck, you will find everything you need to understand the market
The femtech market is moving fast, with new deals, products, and policies appearing almost every week.
In this blog post, we cover the latest news shaping the femtech market, from fertility infrastructure consolidation to AI-powered women's health tools.
We constantly update this blog post so you always have a clear view of what is happening in the femtech market.
And if you want to better understand this new industry, you can download our pitch covering the femtech market.
Insights
- The femtech market is now seeing real infrastructure plays, with Reprotech and TMRW combining to build the largest technology-enabled cryostorage company in fertility, a sign that back-end systems are becoming as valuable as front-end apps.
- Hologic's latest Global Women's Health Index shows that 1.5 billion women and girls missed essential preventive tests in the past year, pointing to a huge unmet need that the femtech market still has to solve.
- Big consumer brands are entering the femtech market, with Costco teaming up with Sesame and IVI RMA to offer fertility care plus 80% medication savings to its members.
- Aavia's dataset of more than 250 million cycle-anchored data points shows that proprietary female-specific data is becoming a real moat in the femtech market, especially for AI-driven products.
- Menopause is emerging as one of the strongest sub-segments of the femtech market, with Sword expanding Bloom into a full life-stage platform and Coral raising C$4 million to scale menopause care across Canada.
- Oura's launch of a proprietary AI model built specifically for women's health suggests that generic wellness AI is no longer enough to compete in the femtech market.
- Pharma is still a credible buyer in the femtech market, as shown by Gedeon Richter acquiring Celmatix's discovery portfolio covering fertility, endometriosis, and ovarian aging.
- Nutrition is moving from premium consumer spending toward clinical care pathways in the femtech market, with Epicured acquiring Chiyo to push women's nutrition into reimbursable healthcare.
- Seed-stage femtech market companies like myStoria are expanding from single use cases such as fertility into broader reproductive health coordination covering endometriosis, PCOS, and perimenopause.
- Regulators are getting involved in the femtech market, with HHS and the American Urological Association signing a formal collaboration to advance menopause care and local estrogen therapy education.
- At-home diagnostics keep leveling up in the femtech market, as Inito launched a wireless reader that tracks four fertility hormones on a single strip across both iOS and Android.
This chart, included in our femtech market deck, shows how Flo Health is capturing share in femtech
Summary table of the latest news in the femtech market
We define the femtech market as technology-enabled products and services that address women's reproductive and other female-specific health needs.
We include solutions focused on menstrual and cycle health, fertility and contraception, pregnancy and postpartum, menopause, pelvic and sexual health, and clinically oriented tools for conditions that predominantly or uniquely affect women such as breast and gynecological cancers.
We exclude general-purpose health, wellness, fitness, mental health, and consumer apps that are not specifically designed around women's biology, care pathways, or life stages.
You can also read our detailed analysis to understand what are the quarterly updates in the femtech market.
| News | Category | Date | Source |
|---|---|---|---|
| Inito launched a wireless fertility reader that tracks four hormones. | Product launches | April 9, 2026 | Inito |
| Oura launched a women's-health AI model, not a generic chatbot. | Breakthrough | April 8, 2026 | Oura Ring |
| Reprotech and TMRW combined to create a fertility storage giant. | M&A | April 2, 2026 | PR Newswire |
| Aavia published one of the largest cycle-anchored women's health datasets. | Market Research | April 2, 2026 | Aavia |
| myStoria raised seed money and expanded beyond fertility. | Fundraisings | March 31, 2026 | myStoria |
| Coral raised more money to scale menopause care across Canada. | Fundraisings | March 31, 2026 | Business Wire |
| Hologic said 1.5 billion women still miss key preventive tests. | Market Research | March 17, 2026 | Hologic |
| HHS and AUA signed a menopause-focused women's health pact. | Regulations & Policies | March 12, 2026 | HHS.gov |
| Costco, Sesame, and IVI RMA teamed up to widen fertility access. | Partnerships | March 9, 2026 | Business Wire |
| Sword turned Bloom into a full life-stage women's health platform. | Product launches | March 5, 2026 | Sword Health |
| Richter bought Celmatix assets to deepen its women's health pipeline. | M&A | March 3, 2026 | Gedeon Richter |
| Epicured bought Chiyo to push women's nutrition into healthcare. | M&A | February 19, 2026 | PR Newswire |
Latest news of the femtech market
Inito launched the most precise at-home hormone tracker the femtech market has seen so far
Product launches
What happened?
Inito launched the InSight Wireless Reader, a Wi-Fi-enabled home fertility device that tracks four hormones on a single test strip. The new Inito reader also works across both iOS and Android, making it easier to use day to day.
When was it?
Inito announced the launch on April 9, 2026.
Why is it big news?
This Inito launch shows that at-home diagnostics in the femtech market are getting more precise, more connected, and more accessible to everyday users.
Why should you care?
If you're an investor in the femtech market, better hardware and smoother onboarding can meaningfully improve retention and revenue in at-home diagnostics. If you're an entrepreneur in the femtech market, this launch confirms that ease of use can matter as much as the science behind the product.
As this chart shows, and as featured in our femtech market deck, search interest in femtech has increased significantly
Oura built the first proprietary AI model dedicated to women's health in the femtech market
Breakthrough
What happened?
Oura launched its first proprietary AI model designed specifically for women's health. The Oura model combines clinical guidance, biometric data, and long-term trends instead of relying on a one-size-fits-all AI approach.
When was it?
Oura unveiled the new AI model on April 8, 2026.
Why is it big news?
This Oura move signals that women's health is now a core AI product area in the femtech market, not just a feature inside general wellness apps.
Why should you care?
If you're an investor in the femtech market, the bar is rising, and future winners will likely need female-specific data and strong clinical grounding. If you're an entrepreneur in the femtech market, generic AI may no longer be enough and sharper product positioning becomes essential.
This chart, included in our femtech market deck, compares the main business model options for menopause telehealth platforms
Reprotech and TMRW merged to create the biggest fertility storage company in the femtech market
M&A
What happened?
Reprotech and TMRW Life Sciences announced a business combination to create the most comprehensive technology-enabled cryostorage company in fertility. The new group brings together long-running cryostorage operations with digital tracking and automation for frozen eggs, embryos, and sperm.
When was it?
The combination was announced on April 2, 2026.
Why is it big news?
This Reprotech and TMRW deal is a market-structure move in the femtech market, reshaping the fertility infrastructure layer that more and more families now rely on.
Why should you care?
If you're an investor in the femtech market, bigger infrastructure players can become hard to displace when storage, traceability, and trust all matter. If you're an entrepreneur in the femtech market, fertility is moving beyond clinics and apps, so your product needs to plug into this emerging infrastructure stack.
This market map, featured in our femtech market deck, highlights top companies and startups in the femtech market
Aavia released one of the largest cycle-anchored datasets ever seen in the femtech market
Market Research
What happened?
Aavia published findings built on more than 250 million cycle-anchored data points. Aavia argues that hormone-cycle-aware data can reveal earlier patterns in conditions such as PMDD and PCOS.
When was it?
Aavia shared these findings on April 2, 2026.
Why is it big news?
This Aavia release pushes the idea that the femtech market needs better female-specific data, not just more data, to build truly useful products.
Why should you care?
If you're an investor in the femtech market, proprietary cycle-anchored data can become a moat, especially in AI, diagnosis support, and personalized care. If you're an entrepreneur in the femtech market, the structure of your data matters, and products built around women's biology need data models that actually reflect it.
This chart, featured in our femtech market deck, illustrates how revenue is divided among customer segments in the femtech market
myStoria closed a $1.625 million seed round and widened its scope in the femtech market
Fundraisings
What happened?
myStoria announced a $1.625 million seed round and said the company is expanding from fertility into the broader reproductive health lifecycle. The myStoria platform will now cover conditions such as endometriosis, PCOS, and perimenopause.
When was it?
myStoria shared the news on March 31, 2026.
Why is it big news?
This myStoria round shows where younger femtech market companies are heading, moving from a single use case into broader care coordination.
Why should you care?
If you're an investor in the femtech market, capital is still flowing into reproductive-health workflow and navigation tools, not only into big clinics or devices. If you're an entrepreneur in the femtech market, a narrow entry point can still work, but a clear expansion path into care coordination is becoming a real wedge.
This chart, included in our femtech market deck, shows annual VC investment in femtech startups
Coral raised C$4 million to scale menopause care nationwide in the femtech market
Fundraisings
What happened?
Coral Health announced a C$4 million acceleration round. Coral said the new funding will support national expansion of its integrated platform for midlife women across Canada.
When was it?
Coral shared the funding news on March 31, 2026.
Why is it big news?
This Coral round confirms that menopause remains one of the strongest sub-markets in the femtech market, with real investor appetite for focused operators outside the U.S.
Why should you care?
If you're an investor in the femtech market, menopause care is shaping up to be an enduring market rather than a short-term trend. If you're an entrepreneur in the femtech market, clear positioning around one life stage can still attract capital when the problem is painful and the business model is practical.
This chart, included in our femtech market deck, shows annual funding in femtech startups
Hologic revealed that 1.5 billion women are still missing essential care in the femtech market
Market Research
What happened?
Hologic released the fifth Global Women's Health Index with Gallup. The Hologic report said over half of women and girls aged 15 and older were not tested in the past year for cancer, high blood pressure, diabetes, or STIs.
When was it?
Hologic published the report on March 17, 2026.
Why is it big news?
This Hologic number is huge and shows that the femtech market gap is still massive, especially around screening and prevention.
Why should you care?
If you're an investor in the femtech market, such a big unmet need often points to large market potential in diagnostics, access, remote screening, and triage. If you're an entrepreneur in the femtech market, the report highlights where the real pain points are, so you can build around genuine gaps instead of trendy ideas.
In our femtech market deck, we tell you what to focus on
HHS and AUA signed a landmark menopause collaboration that changes the femtech market
Regulations & Policies
What happened?
HHS, through the Office on Women's Health, announced a formal memorandum with the American Urological Association and related groups. The goal is to improve evidence-based use of local estrogen therapy for postmenopausal women, especially for genitourinary syndrome of menopause and recurrent UTIs.
When was it?
HHS and AUA announced the collaboration on March 12, 2026.
Why is it big news?
This HHS and AUA collaboration can change how doctors are educated and how care standards spread in the femtech market, especially in menopause care where adoption has often lagged.
Why should you care?
If you're an investor in the femtech market, policy support can unlock demand and reduce friction for menopause-focused services, treatments, and education tools. If you're an entrepreneur in the femtech market working on menopause care, this signals that the segment is becoming more institutionally supported and easier to sell into.
In our femtech market deck, we identify pain points entrepreneurs should prioritize
Costco joined Sesame and IVI RMA to make fertility care mainstream in the femtech market
Partnerships
What happened?
Costco, Sesame, and IVI RMA North America announced a new fertility partnership. The offer combines coordinated intake, fertility workups, specialist referral, and up to 80% medication savings for Costco members.
When was it?
The partnership was announced on March 9, 2026.
Why is it big news?
This Costco partnership helps bring fertility care closer to a retail-like access model in the femtech market, making it feel more like normal healthcare purchasing.
Why should you care?
If you're an investor in the femtech market, distribution matters, and partnerships with large member bases can speed growth faster than direct-to-consumer marketing alone. If you're an entrepreneur in the femtech market, big non-healthcare brands can become powerful go-to-market channels, with affordability and access becoming real product features.
In our femtech market deck, we dentify risks investors and builders need to be aware of
Sword expanded Bloom into a full life-stage platform for the femtech market
Product launches
What happened?
Sword Health expanded Bloom from pelvic health into a broader women's health platform. Sword launched with a menopause program and said the Bloom platform will support women across life stages instead of treating each issue as a separate product.
When was it?
Sword announced the expansion on March 5, 2026.
Why is it big news?
This Sword move is a strong signal that the femtech market is shifting from narrow point solutions to broader platforms, which can reshape employer buying and vendor consolidation.
Why should you care?
If you're an investor in the femtech market, platform models can capture more revenue per customer and lower churn when they solve multiple needs over time. If you're an entrepreneur in the femtech market, a single-feature product may become harder to defend, so partnerships, deeper specialization, or a broader roadmap may be needed.
In our femtech market deck, we ensure you have the latest information
Gedeon Richter bought Celmatix's discovery portfolio to go deeper into the femtech market
M&A
What happened?
Gedeon Richter acquired Celmatix's women's health discovery portfolio. The deal adds programs tied to fertility, endometriosis, and ovarian aging to Richter's pipeline.
When was it?
Richter announced the acquisition on March 3, 2026.
Why is it big news?
This Richter and Celmatix deal is concrete proof that established pharma still sees women's health assets in the femtech market as strategic, not niche.
Why should you care?
If you're an investor in the femtech market, this deal supports the idea that women's health biotech can produce credible exit paths. If you're an entrepreneur in the femtech market building hard science assets, real buyers do exist and strategic value is possible before full commercialization.
In our femtech market deck, we like to quantify things to make things easier to understand
Epicured and Chiyo joined forces to put food at the center of the femtech market
M&A
What happened?
Epicured acquired Chiyo, a women's health nutrition company. The combined Epicured and Chiyo offer aims to bring stage-specific nutrition into more reimbursable and clinical care pathways.
When was it?
The acquisition was announced on February 19, 2026.
Why is it big news?
This Epicured and Chiyo deal signals that nutrition in the femtech market is moving from premium consumer spending toward formal healthcare channels, which can greatly expand reach.
Why should you care?
If you're an investor in the femtech market, reimbursement can turn a business from niche to scalable, and this deal hints at that shift. If you're an entrepreneur in the femtech market, consumer demand alone is not enough, so tying your solution into payer and provider systems is becoming more important.
Related blog posts
- The latest developments in the femtech market
- The latest funding news in the femtech market
- What is the true size of the femtech market?
- How funding activity has evolved in the femtech market
- What are the key fundraising trends in the femtech market?
- All the funding deals announced in the femtech market
- A complete list of business models in the femtech market
- Which companies have raised the most funding in the femtech market?
- Which companies are the most valued in the femtech market?
